Article

The implementation of liquid biopsies in routine care of patients with advanced solid cancer (LIQPLAT): a study protocol for a single arm trial

2025-02-13

Abstract excerpt

<h4>Background: </h4> Advanced solid cancers present significant treatment challenges due to their genomic heterogeneity and resistance. Liquid biopsies, specifically circulating tumour DNA (ctDNA), have emerged as promising tools to support treatment decision making. However, evidence regarding their implementation in routine care remains limited. <h4>Methods: </h4>: LIQPLAT is a single-arm trial (SAT), assessing...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 903a465e-e511-5eb2-85ec-c1f9f6c7188d
DOI: 10.1101/2025.02.13.25322206

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

The implementation of liquid biopsies in routine care of patients with advanced solid cancer (LIQPLAT): a study protocol for a single arm trialDOI 10.1101/2025.02.13.25322206Read

Multi-Analyte Liquid Biopsies for Treatment Guidance in Advanced Refractory Cancers: Findings of the LIQUID IMPACT TrialSemantic proximity Read

A Review of Circulating Tumor DNA (ctDNA) and the Liquid Biopsy in Cancer Diagnosis, Screening, and Monitoring Treatment ResponseSemantic proximity Read

Liquid biopsy enters the clinic - implementation issues and future challenges.Semantic proximity Read

The potential of liquid biopsies for the early detection of cancerSemantic proximity Read

Genomic profiling and expanded use of targeted anticancer drugs in solid cancers with exhausted evidence-based treatment options: the PRECODE study protocolSemantic proximity Read

Liquid Biopsy in the Clinical Management of CancersSemantic proximity Read

Implementation of a 1021-gene liquid biopsy assay for real-world tumor genomic profiling in oncology practice.Semantic proximity Read

Implementation of circulating tumour DNA multi-target mutation testing in plasma: a perspective from an external quality assessment providers' survey.Semantic proximity Read

Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA WorkshopSemantic proximity Read

Lessons from a National Liquid Biopsy Program to Provide Cancer Testing and Treatment for Patients with Advanced Solid Tumors.Semantic proximity Read

Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapiesSemantic proximity Read

Unlocking precision oncology by establishing a nationwide comprehensive genomic profiling and molecular tumor board platform for patients with advanced cancer: the BALLETT studySemantic proximity Read